C4 Therapeutics announced the departure of Chief Accounting Officer Mark Mossler and appointed CFO Kendra R. Adams as his successor, effective May 15, 2026.
Key takeaways
Mark Mossler will step down as Chief Accounting Officer effective May 15, 2026, with no disagreement with the company.
CFO Kendra R. Adams will assume the additional role of principal accounting officer effective the same date.
Adams will not receive extra compensation for the added role, and no changes to her existing plans or arrangements.
The departure and appointment are routine executive changes with no disclosed financial impact.